Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes

18 de novembro de 2016 atualizado por: GlaxoSmithKline

A Pharmacy Based Open Study to Evaluate Whether Pack Size Affects Compliance for Subjects Diagnosed With Diabetes Type II Who Are Established on Metformin Treatment

MTF116086 is an open-label, randomised, parallel-design study in subjects with type II diabetes. The study is site-based, with local pharmacies serving as the sites and pharmacists as principal investigators for the sites. All subjects will enter an initial 8-week observational phase during which purchase behaviour and compliance with usual metformin use will be observed and recorded. At the end of the observational phase, subjects will be randomised to one of the two arms (metformin small pack vs. metformin large pack) for a 20-week interventional phase. The medication in the interventional phase is provided to the subjects free of charge. HbA1c will be collected for all subjects during Week 0, Week 8, and Week 28. Subjects will be asked questions about their tablet compliance, their satisfaction with the pack size they received and reasons for missing doses throughout the interventional phase by the pharmacist. The pharmacy visit on Week 28 will be end of the study.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

31

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Correintes, Argentina
        • GSK Investigational Site
      • Corrientes, Argentina
        • GSK Investigational Site
      • Mendoza, Argentina, 5515
        • GSK Investigational Site
      • Mendoza, Argentina, 5539
        • GSK Investigational Site
      • Mendoza, Argentina
        • GSK Investigational Site
      • Provincia de Buenos Aires, Argentina, 1754
        • GSK Investigational Site
      • Tucumán, Argentina, T 4000IOE
        • GSK Investigational Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Males and females of age >=18 years
  • Diagnosis of type II diabetes
  • HbA1c value no higher than 9.0%
  • Evidence of physician-supplied prescription for metformin use
  • Stable dose of metformin for 3 months prior to enrolment
  • Written informed consent from the subject

Exclusion Criteria:

  • Current use of any anti-diabetic medication other than metformin

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Metformin Small Pack Arm
All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin small pack arm will receive medication free of charge in a small pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
Experimental: Metformin Large Pack Arm
All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin large pack arm will receive medication free of charge in a large, monthly pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
The large pack will consist of 1 month's supply of metformin.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in HbA1c Values at Week 28
Prazo: Baseline (Week 8) and Week 28
HbA1c was tested with a point-of-care device, which required a finger prick to obtain blood and provided an immediate result upon analysis in the device. HbA1c was tested at pharmacy visits corresponding to three time points: enrollment (Week 0), Baseline (Week 8), and End of Study (Week 28). The difference in the mean change from Baseline was to be calculated between the treatment arms (small pack minus large pack), and the 2-sided 95% confidence interval for the difference in mean change in HbA1c was to be calculated. However, because the study was terminated early, and the sample size was reduced, the statistical hypotheses defined in the protocol were not tested due to insufficient power. Therefore, the final analyses were limited to descriptive statistics. The percentage HbA1c is a measure of how much of the hemoglobin in the blood has become glycated (chemically bounded to glucose).
Baseline (Week 8) and Week 28

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Mean Percent Compliance Throughout the Interventional Phase
Prazo: From Randomization to Week 28
Compliance for the study was estimated as a percentage, with the denominator defined as the number of pills dispensed by the pharmacist and the numerator defined as the number of pills taken, accounting for remaining pills at subsequent pharmacy visits.
From Randomization to Week 28
Mean Percent Compliance Throughout the Observational Phase, Per Treatment They Were Randomized to in the Interventional Phase
Prazo: From enrollment to Week 8
Compliance was estimated during the 8-week Observational Phase for usual metformin treatment. During the Observational Phase, compliance was measured by monitoring the number of pill dispensed and the return of the pills or tablets.
From enrollment to Week 8
Number of Participants Who Took Zero Metformin Pills for the Indicated Number of Days
Prazo: Week 28
The number of days on which no metformin pills were taken by participants was summarized.
Week 28
Number of Participants With Diabetes Disease Management Modifications
Prazo: Week 28
Throughout the duration of the study, participants remained on their recommended metformin dosing regimens, unless a change in metformin dose was prescribed by their physician. The number of participants who received additional diabetes therapy for the management of diabetes was summarized.
Week 28
Number of Participants Who Required a Non-routine Health Care Professional Visit for Diabetes
Prazo: Week 28
The number of participants who visited a health care professional for diabetes management during the study was summarized.
Week 28
Number of Participants Who Preferred Their Treatment Regimens (Interventional Arm Treatment [Large or Small Pack Metformin]) to How They Previously Took Their Medication
Prazo: Week 28
Number of participants who preferred their treatment regimens (interventional arm treatment [large or small pack metformin]) to how they previously took their medication are presented.
Week 28
Number of Participants Who Missed Metformin Days/Doses for the Indicated Reasons
Prazo: Week 28
The number of particiapnts who missed days or doses of metformin was summarized.
Week 28
Number of Participants Withdrawn From the Study Due to the Following Reasons: Withdrawal of Informed Consent; Lost to Follow-up
Prazo: Week 28
The number of participants who voluntarily discontinued participation in the study at any time or who were withdrawn by the investigator for pre-defined reasons was summarized.
Week 28

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de maio de 2013

Conclusão Primária (Real)

1 de fevereiro de 2014

Conclusão do estudo (Real)

1 de fevereiro de 2014

Datas de inscrição no estudo

Enviado pela primeira vez

21 de março de 2013

Enviado pela primeira vez que atendeu aos critérios de CQ

21 de março de 2013

Primeira postagem (Estimativa)

25 de março de 2013

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

9 de janeiro de 2017

Última atualização enviada que atendeu aos critérios de controle de qualidade

18 de novembro de 2016

Última verificação

1 de novembro de 2016

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Dados/documentos do estudo

  1. Formulário de Relato de Caso Anotado
    Identificador de informação: 116086
    Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
  2. Relatório de Estudo Clínico
    Identificador de informação: 116086
    Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
  3. Conjunto de dados de participantes individuais
    Identificador de informação: 116086
    Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
  4. Formulário de Consentimento Informado
    Identificador de informação: 116086
    Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
  5. Protocolo de estudo
    Identificador de informação: 116086
    Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
  6. Especificação do conjunto de dados
    Identificador de informação: 116086
    Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
  7. Plano de Análise Estatística
    Identificador de informação: 116086
    Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever